Kolon Life Science "Anti-cancer Virus" KLS-3020 "Phase 1 Next Year" – Diodeo

(Seoul = News 1) Lee Young-sung, president of Kolon Life Science, announced on the 10th that he planned to enter the pre-clinical phase (animal testing) of the anti-cancer virus & # 39; ; KLS-3020 & # 39; Lee Woo-suk, CEO of Kolon Life Science, said: "The preclinical trials KLS-3020 took place at a press conference held at Kolon-on- I will be applying for the first phase of the Food and Drug US Administration (FDA) by the end of next year. "

& # 39; KLS-3020 & # 39; has a mechanism of action similar to that of the famous viral cancer drug, Pegsabek & # 39; in Korea. When the virus is injected into the tumor cells, the virus grows, causing the tumor cells to burst and the immune cells to congregate and attack the tumor cells.

"PeSabec" is currently undergoing Phase III clinical trials. It should be published sooner than the "KLS-3020", which will enter clinical phase 1 at the end of next year. As a result, Kolon Life Science is advocating for a more competitive treatment by reinforcing the therapeutic effect of & KLS-3020 & # 39;. "KLS-3020 is similar to Peplabek in Sirajen, but it has increased lysis of tumor cells and the activity of immune cells," Lee said.

The confidence of Kolon Life Science comes from the technology 'Fox Virus Promoter & # 39; applied to the development of & # 39; KLS-3020 & # 39 ;. The "Fox Virus Promoter" is a kind of initiator technology that can strongly induce the gene expression of the "KLS-3020" component and increase the therapeutic efficacy. Kolon Life Sciences acquired a national patent for this technology last month.

Lee Woo-suk, representative of Kolon Life Science, said: "KLS-3020 is a substance that has introduced several therapeutic genes into viral species with excellent efficacy and safety, confirming the therapeutic efficacy of various animal models of cancer. "He added.

In addition, Kolon Life Sciences added KLS-2031, a gene pain medication, to the new drug pipeline. & # 39; KLS-2031 & # 39; will apply to the Phase 1 clinical study at the end of this year and plans to enter the clinic from next year.

[email protected]